Cita APA (7a ed.)
Wang, M., Kuang, Y., Gong, L., Hua, Y., Pei, Q., Guo, C., . . . Yang, G. (2020). First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Investigational New Drugs, 38(6), 1826-1836.
Cita Chicago Style (17a ed.)
Wang, Meng-na, Yun Kuang, Li-ying Gong, Ye Hua, Qi Pei, Cheng-xian Guo, Yu Cao, Jie Huang, y Guo-ping Yang. "First-in-human, Phase I Single-ascending-dose Study of the Safety, Pharmacokinetics, and Relative Bioavailability of Selatinib, a Dual EGFR-ErbB2 Inhibitor in Healthy Subjects." Investigational New Drugs 38, no. 6 (2020): 1826-1836.
Cita MLA (9a ed.)
Wang, Meng-na, et al. "First-in-human, Phase I Single-ascending-dose Study of the Safety, Pharmacokinetics, and Relative Bioavailability of Selatinib, a Dual EGFR-ErbB2 Inhibitor in Healthy Subjects." Investigational New Drugs, vol. 38, no. 6, 2020, pp. 1826-1836.
Precaución: Estas citas no son 100% exactas.